Skin Cancer Treatment Denied by Insurance? How to Appeal

Skin cancer is the most common cancer in the United States, and treatment options have advanced dramatically — particularly for advanced or metastatic disease. Yet insurance denials for skin cancer treatments, including immunotherapy for melanoma, targeted agents for advanced basal cell, and sentinel lymph node biopsy (SLNB), remain frustratingly common. Here is how to appeal.

Melanoma: Immunotherapy and Targeted Therapy Denials

Advanced melanoma treatment has been transformed by checkpoint inhibitors and BRAF-targeted therapies. Insurance denials typically arise around:

Keytruda (pembrolizumab) and Opdivo (nivolumab): PD-1 checkpoint inhibitors FDA-approved for advanced and metastatic melanoma. Common denial reasons include step therapy requirements to try BRAF-targeted therapy first in BRAF-mutant patients, or "not medically necessary" claims when tumor staging documentation is incomplete.

Your appeal for checkpoint inhibitor therapy should include:

• Pathology report with BRAF V600E/K mutation status
• AJCC staging documentation (Stage III unresectable or Stage IV)
• PD-L1 expression testing results if available
• Reference to NCCN (National Comprehensive Cancer Network) Melanoma Guidelines recommending immunotherapy as first-line for metastatic disease
• Oncology and dermatology co-management notes

BRAF/MEK inhibitors: For BRAF V600-mutant melanoma, BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (trametinib, cobimetinib) are also covered under NCCN guidelines. If denied for combination BRAF+MEK therapy, cite the clinical trial data showing superior outcomes with combination vs. monotherapy.

Adjuvant therapy for resected Stage III: Pembrolizumab and nivolumab are also FDA-approved adjuvant therapies following complete resection of Stage III melanoma. These may be denied as "unnecessary" post-surgery — appeal by citing FDA approval and NCCN adjuvant recommendations.

Basal Cell Carcinoma: Hedgehog Pathway Inhibitors

For locally advanced or metastatic BCC not amenable to surgery or radiation:

Erivedge (vismodegib) and Odomzo (sonidegib): Hedgehog pathway inhibitors (smoothened inhibitors) FDA-approved for locally advanced BCC after surgery or radiation is not an option, and for metastatic BCC. Common denial reasons:

• Insurer argues surgery or radiation should be tried first
• Documentation of "locally advanced" status is insufficient
• Formulary tier placement requiring step therapy

Your appeal should document:

• Multidisciplinary tumor board review confirming inoperability
• Size and invasion depth of tumor
• Prior surgery or radiation history and why re-treatment is not feasible
• FDA-approved indication for locally advanced or metastatic BCC
• NCCN BCC guidelines recommending hedgehog inhibitors for appropriate patients

Squamous Cell Carcinoma: Libtayo and Advanced SCC

Libtayo (cemiplimab): PD-1 inhibitor FDA-approved for metastatic or locally advanced cSCC not eligible for curative surgery or radiation. Also approved for advanced BCC after hedgehog inhibitor failure.

For Libtayo denials, document:

• Pathology confirming cutaneous SCC (not mucosal SCC, which has different treatment protocols)
• Clinical staging showing locally advanced or metastatic disease
• Why surgery or radiation is not curative in this case
• NCCN CSCC guidelines recommending cemiplimab for appropriate patients

Sentinel Lymph Node Biopsy (SLNB) Denials

SLNB is a staging procedure for melanoma, performed to identify whether cancer has spread to regional lymph nodes. Insurance denials for SLNB in melanoma occur when:

• Tumor thickness threshold is disputed (generally indicated for Breslow depth 0.8mm or greater)
• Insurer classifies it as elective or optional
• Coding dispute between surgical excision and biopsy CPT codes

Your appeal should document:

• Breslow depth from pathology report
• NCCN staging criteria requiring SLNB
• Expected change in treatment management based on SLNB results (sentinel node positivity changes staging to Stage III, requiring adjuvant therapy)
• Dermatopathology report indicating ulceration, high mitotic rate, or other features warranting SLNB

NCCN Guidelines as the Gold Standard

NCCN (nccn.org) publishes free-to-access clinical practice guidelines for every skin cancer type. These guidelines are the most widely accepted standards in oncology and are explicitly referenced by CMS and many private payers. Always cite the specific NCCN category of recommendation (Category 1, 2A, 2B) for the treatment you're appealing.

For external appeals of skin cancer denials, NCCN guidelines carry significant weight with IROs) Explained" class="auto-link">independent review organizations.

Fight Back With ClaimBack

ClaimBack helps you build skin cancer appeals with NCCN guideline references, staging documentation frameworks, and immunotherapy step therapy rebuttals.

Start your free appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal